IDEAYA Biosciences $92 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with a public offering of 8,761,905 shares of common stock of IDEAYA Biosciences, Inc. at $10.50 per share, which included 1,142,857 shares from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of $92 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IDYA.”
Based in South San Francisco, California, IDEAYA is a clinical stage oncology-focused precision medicine company developing targeted therapeutics for patients selected using molecular diagnostics across multiple oncology indications.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow, Jonathan Bye and Elsie Cheang. The tax team included partner Kara L. Mungovan and associate William Liang. The intellectual property and technology transactions team included partner David R. Bauer and associate S. Dream Montgomery. Members of the Davis Polk team are based in the Northern California and New York offices.